Helicobacter pylori and different topographic types of gastritis. Treatment response after successful eradication therapy in functional dyspepsia

Scandinavian Journal of Gastroenterology

Volumn 37, Issue 7, 2002, Pages 778-784

  Koskenpato, Jari ^a   Farkkila M ^a   Sipponen, P ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Eradication therapy; Functional dyspepsia; Gastritis; Gastritis subtypes; Helicobacter pylori

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; METRONIDAZOLE; OMEPRAZOLE; PLACEBO; UREASE; ANTIINFECTIVE AGENT; ANTIULCER AGENT; DIAGNOSTIC AGENT;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; CHRONIC GASTRITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE SEVERITY; DYSPEPSIA; ENZYME ACTIVITY; ERADICATION THERAPY; FOLLOW UP; GASTRITIS; GASTROINTESTINAL SYMPTOM; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; STANDARDIZATION; STOMACH ACID SECRETION; STOMACH ANTRUM; STOMACH BIOPSY; TREATMENT OUTCOME; UREA BREATH TEST; BIOPSY; BREATH ANALYSIS; CHRONIC DISEASE; COMPARATIVE STUDY; DRUG COMBINATION; FEMALE; ISOLATION AND PURIFICATION; MALE; METHODOLOGY; MICROBIOLOGY; MIDDLE AGED; PATHOLOGY; STOMACH MUCOSA;

AMOXICILLIN; ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; BIOPSY; BREATH TESTS; CHRONIC DISEASE; DRUG THERAPY, COMBINATION; DYSPEPSIA; FEMALE; GASTRIC MUCOSA; GASTRITIS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; METRONIDAZOLE; MIDDLE AGED; OMEPRAZOLE; UREASE;

EID: 0035988881     PISSN: 00365521     EISSN: None     Source Type: Journal    
DOI: 10.1080/gas.37.7.778.784     Document Type: Article

References (37)

1. Pathogenic mechanisms of Helicobacter pylori
2. Hypotheses on the pathogenesis and natural history of Helicobacter pylori-induced inflammation
3. Eradicating Helicobacter pylori infection lowers gastrin mediated acid secretion by two-thirds in patients with duodenal ulcer
4. Helicobacter pylori and disturbance of gastric function associated with duodenal ulcer disease and gastric cancer
5. Ulcer and gastritis
6. Chronic gastritis: Progression of inflammation and atrophy in a six-year endoscopic follow-up of a random sample of 142 Estonian urban subjects
7. Role of Helicobacter pylori in the pathogenesis of gastritis, peptic ulcer and gastric cancer
8. Chronic gastritis and duodenal ulcer: A case control study on risk of coexisting duodenal or gastric ulcer in patients with gastritis
9. Young onset peptic ulcer disease and non-ulcer dyspepsia are separate entities
10. Cumulative 10-year risk of symptomatic duodenal and gastric ulcer in patients with or without chronic gastritis. A clinical follow-up study of 454 outpatients
11. Systematic review and economic evaluation at Helicobacter pylori eradication treatment for non ulcer dyspepsia
12. H. pylori therapy is not effective for treatment of non-ulcer dyspepsia: Meta-analysis of randomized controlled trials
13. Helicobacter pylori infection in non-ulcer dyspeptic and ulcer patients: Determinants and consequences in 'real life'
14. Quantitative analysis of symptoms of non-ulcer dyspepsia as related to age, pathology, and Helicobacter infection
15. Dyspepsia in general practice: History and symptoms in relation to Helicobacter pylori serum antibodies
16. Symptomatic benefit from eradicating Helicobacter pylori infection in patients with nonulcer dyspepsia
17. Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia
18. Absence of benefit of eradicating Helicobacter pylori in patients with nonulcer dyspepsia
19. Eradication of Helicobacter pylori in functional dyspepsia: Randomised double blind placebo controlled trial with 12 months' follow up
20. The 13C-urea breath test as a predictor of intragastric bacterial load and severity of Helicobacter pylori gastritis
21. The Sydney system: Histological division
22. The European 13C-urea breath test for the detection of Helicobacter pylori
23. Etiology of dyspepsia: Four hundred unselected consecutive patients in general practice
24. Association of CagA-positive and CagA-negative Helicobacter pylori strains with patients' symptoms and gastritis in primary care patients with functional upper abdominal complaints
25. Distinct profiles of gastritis in dyspepsia subgroups. Their different clinical responses to gastritis healing after Helicobacter pylori eradication
26. Disappearance of gastritis after eradication of Helicobacter pylori
27. Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during 12-months of treatment with omeprazole and lanzoprazole in patients with gastro-oesophageal reflux disease
28. Changes in Helicobacter pylori-induced gastritis in the antrum and corpus under 12 months of treatment with ranitidine and lanzoprazole in patients with duodenal ulcer disease
29. Impact of functional dyspepsia on quality of life and health care consumption after cessation of antisecretory treatment. A multicentre 3-month follow-up study
30. Longterm acid suppressing treatment in general practice
31. Efficacy of omeprazole in functional dyspepsia: Double-blind, randomized, placebo-controlled trials (the Bond and Opera studies)
32. Essential role of urease in pathogenesis of gastritis induced by Helicobacter pylori in gnotobiotic piglets
33. A urease-negative mutant of Helicobacter pylori constructed by allelic exchange mutagenesis lacks the ability to colonize the nude mouse stomach
34. Further evidence of the toxic effect of ammonia produced by Helicobacter pylori urease on human epithelial cells
35. Highly significant role of Helicobacter pylori urease in phagocytosis and production of oxygen metabolites by human granulocytes
36. Helicobacter pylori infection density and gastric inflammation in duodenal ulcer and non-ulcer subjects
37. Global view of Helicobacter pylori associated gastritis